Compare YMT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | ATYR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 295.5K | 322.6K |
| IPO Year | 2023 | 2015 |
| Metric | YMT | ATYR |
|---|---|---|
| Price | $0.27 | $7.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $60.25 |
| AVG Volume (30 Days) | 205.7K | ★ 1.5M |
| Earning Date | 06-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.12 | $0.10 |
| 52 Week High | $3.45 | $7.78 |
| Indicator | YMT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 22.58 | 85.78 |
| Support Level | $0.14 | $0.53 |
| Resistance Level | $0.35 | N/A |
| Average True Range (ATR) | 0.06 | 0.75 |
| MACD | 0.01 | 0.55 |
| Stochastic Oscillator | 4.09 | 93.40 |
Yimutian Inc operates an agricultural B2B platform in China. It provides a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching and matching to transaction facilitation and settlement, through its Yimutian App and Douniu App. Additionally, leveraging its industry experience and market insights, the company has ventured into the realm of smart farming and agricultural sourcing and trading, further broadening its commercialization channels and animating its other business lines. The company operates as a single operating and reportable segment, as it offers a unified set of products and services mainly related to the provision of digital agricultural transaction services.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).